Skip to main content

Patient Support Line 1-866-433-8000, Monday - Friday: 8:00 AM to 8:00 PM ET

A man and woman look at each other in a crowded room overlooking a skyline.

How Does KISQALI Work for Early Breast Cancer?

KISQALI + an aromatase inhibitor (AI) is MORE effective than an AI alone

For people with HR+, HER2- stage 2 or 3 early breast cancer (eBC) with a high risk of coming back, KISQALI is taken with a specific kind of hormone therapy called an AI.

To understand how KISQALI works with an AI, it's important to understand the role that hormones and hormone receptors play in causing cancer to come back.

Cancer cell before treatment: in HR+, HER2- eBC, estrogen and other hormones trigger proteins called CDK4 and CDK6. These proteins fuel cancer cell growth, which can increase the risk of cancer returning. With KISQALI + an AI: Hormone therapy, such as an AI, works by stopping estrogen. KISQALI is designed to directly block CDK4 and CDK6 proteins.

CDK4/6, cyclin-dependent kinase 4 and 6; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive.

By taking KISQALI + an AI, you are addressing the risk of cancer coming back in 2 different ways

How KISQALI works glossary

Learn more about key terms used on this page by tapping or clicking on the words below.